📰 GeneralCNBCSaturday, October 24, 2026 at 2:30 PM UTC2h ago

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca

Read full article at CNBC →

Originally published by CNBC. Summary and curation by DutyStation News.

← Back to News

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

📰 Related Stories

AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio

PHP-ocalypse: How two critical web bugs almost broke the internet

Retail investors are not more sophisticated than 30 years ago, says former hedge fund manager

LG’s brilliant C6 OLED TV is already $400 off ahead of Black Friday

These clever apps show off the iPhone Duo’s potential

I quit my marketing job to walk dogs for 4 months: It's 'one of the most valuable professional experiences I've ever had'